HF Patients With LVADs Being Treated With SGLT2i

Description

The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).

Conditions

Heart Failure With Reduced Ejection Fraction

Talk to us

Study Overview

On this page

Study Details

Study overview

The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).

Heart Failure Patients With Left Ventricular Assist Devices Being Treated With Sodium-Glucose Co-Transporter 2 Inhibitors

HF Patients With LVADs Being Treated With SGLT2i

Condition
Heart Failure With Reduced Ejection Fraction
Intervention / Treatment

-

Contacts and Locations

Chicago

University of Chicago, Chicago, Illinois, United States, 60637

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. LVAD implantation
  • 2. Have not already been prescribed management with an SGLT2i
  • 3. Estimated glomerular filtration rate (eGFR) ≥ 30 milliliters(ml)/minute(min)/1.73 meter(m)2
  • 4. Age ≥ 18 years-old
  • 5. Able to provide informed consent
  • 1. Diagnosis of Type 1 diabetes mellitus
  • 2. eGFR \< 30 ml/min/1.73 m2
  • 3. Age \< 18 years-old

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Chicago,

Mark Belkin, MD, PRINCIPAL_INVESTIGATOR, University of Chicago

Study Record Dates

2025-06